Pharmaceutical Substances Syntheses, Patents, Applications - Part 10. Reference containing a collection of 2267 active pharmaceutical ingredients, including those launched recently. Listed alphabetically according to their INNs and established a link between INNs, structure, synthesis and production processes, patent and literature situation, medical use, and trade names. For pharmacists and researchers | Aminocaproic acid A 91 5-0X0-10 11 -dihydro-5H-dibenzo o d cyclo-heptene NoBH4 soci2 5-hydroxy-10 1 1 -dihydro-5H-di-benzo a d cycloheptene 5-chloro-10 11 -dihydro-5H-dibenzo a d cycloheptene I h2n. .o ch3 ch3no2 ethyl 7-aminoheptanoote nitromethane H N COOH Amineptine Reference s DOS 2 011 806 Science Union appl. GB-P. . US 3 758 528 Science Union appl. . US 3 821 249 Science Union prior. . Formulation s tabl. 100 mg as hydrochloride Trade Name s F Survector Euthérapic I Maneon Poli 1983 1978 wfm 1999 Survector Stroder 1983 Aminocaproic acid atc B02AA01 Acide aminocaproique Epsilcapramin Use antifibrino RN 60-32-2 MF C6H 3NO2 MW EINECS 200-469-3 LD50 4900 mg kg M . g kg M . 3300 mg kg R . 7 g kg dog . CN 6-aminohexanoic acid -Nx O H20 250 C H2N COOH caprolactam Aminocaproic acid Reference s US 2 453 234 American Enka Corp. 1948 NL-prior. 1946 . Formula ion s inj. flask 250 mg ml syrup 25 tabl. 500 mg Trade Name s D Epsilon-Aminocapronsaure Roche Roche wfm Epsilon-Tachostypan Hormon-Chemie -comb. wfm F I J Hexalense Leurquin Caprolisin Malesci Capusumine Nichiiko Hemotin Hokuriku Ipsilon Daiichi Resplamin Kyorin USA Amicar Immunex 92 A Aminoglutethimide Aminoglutéthimide ATC J04AA01 Use antineoplastic aromatase inhibitor RN 125-84-8 MF C13H16N2O2 MW EINECS 204-756-4 LD5 i 625 mg kg M . CN 3- 4-aminopheny l -3-ethyl-2 6-piperidinedione glutethimide q- v hno3 h2so4 -------------- 2-ethylglutorimide I 2-phenyl-butyronitrile 5 O c6h5-ch2-n ch3 3 oh --------------------------- methyl acrylate no2 2- 4-nitrophenyl - butyronitrile CHjCOOH H2SO4 ÏI -------------------- Aminoglutéthimide Reference s US 2 848 455 Ciba 1958 CH-prior. 1955 . racemate resolution Finch N. et al. Experientia EXPEAM 31 1002 1975 . Formulation s tabl. 250 mg Trade Name s D Orimeten Novartis F Orimétène Novartis USA Cytadren Novartis Pharma GB Orimeten Novartis Rodazol Novartis Pharma I Orimeten
